# Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)

> **NCT07276204** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Southern California Institute for Research and Education** · enrollment: 70 (estimated)

## Conditions studied

- MASH - Metabolic Dysfunction-Associated Steatohepatitis

## Interventions

- **DRUG:** Betaine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07276204
- **Lead sponsor:** Southern California Institute for Research and Education
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2029-12-31
- **Final completion:** 2035-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07276204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07276204, "Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07276204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*